QQ客服 官方微博 反馈留言

	Addition of rituximab is not associated with survival benefit compared with CHOP alone for patients with stage I diffuse large B-cell lymphoma
	Jia, Bo; Shi, Yuankai; Kang, Suyi; Yang, Sheng; Hu, Shaoxuan; Li, Yexiong; Dong, Mei; Wang, Weihu; Yang, Jianliang; Zhou, Liqiang
	2015
卷号	27期号:5页码:516-523
关键词	Diffuse large B-cell lymphoma (DLBCL) stage I R-CHOP radiotherapy prognosis
ISSN号	1000-9604
DOI	10.3978/j.issn.1000-9604.2015.10.04
URL标识	查看原文
收录类别	SCIE ; PUBMED ; ISTIC ; CSCD
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/6388267
专题	中国医学科学院 北京协和医学院
推荐引用方式 GB/T 7714	Jia, Bo,Shi, Yuankai,Kang, Suyi,et al. Addition of rituximab is not associated with survival benefit compared with CHOP alone for patients with stage I diffuse large B-cell lymphoma[J],2015,27(5):516-523.
APA	Jia, Bo.,Shi, Yuankai.,Kang, Suyi.,Yang, Sheng.,Hu, Shaoxuan.,...&He, Xiaohui.(2015).Addition of rituximab is not associated with survival benefit compared with CHOP alone for patients with stage I diffuse large B-cell lymphoma.,27(5),516-523.
MLA	Jia, Bo,et al."Addition of rituximab is not associated with survival benefit compared with CHOP alone for patients with stage I diffuse large B-cell lymphoma".27.5(2015):516-523.

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。